International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Therapeutic Role of Kshar in Visha Chikitsa: Ayurveda and Modern Review

Dr. Dholariya Madhavi Chaturbhai[1], Prof (Dr.) Anita Sharma[2], Dr. Dinesh Kumar Kumawat[3]

[1]PG Scholar, Dept. of Agad Tantra evam Vidhi vaidyak, National Institute of Ayurveda (DU), Jaipur
[2]Professor and HOD, Dept. of Agad Tantra evam Vidhi vaidyak National Institute of Ayurveda (DU), Jaipur
[3]Senior Assistant Professor, Dept. of Agad Tantra evam Vidhi vaidyak, National Institute of Ayurveda (DU), Jaipur

Abstract

Background: Kshar (alkaline plant-ash preparations) represents a potent therapeutic category in Ayurvedic pharmacology. Classical treatises document three principal types—Yava Kshar (potassium carbonate-rich), Sarji Kshar (sodium carbonate), and Palash Kshar—for managing envenomation (Visha Chikitsa) from snakes, scorpions, rodents, insects, and plant toxins.

Methods: Following PRISMA guidelines, this comprehensive review collates classical references, formulations, routes of administration, and indications of Kshar in toxicology. These traditional applications are then correlated with contemporary biochemical and toxicological evidence derived from analytical, preclinical, and clinical studies.

Results: Classical applications of Kshar are driven by its Tikshna, Ushna, Krimighna, and Vishaghna properties. Modern preclinical investigations validate its multifaceted role, demonstrating significant anti-inflammatory, antiprotease, phospholipase A2 (PLA2) inhibitory, antimicrobial, and emetic activities. Additionally, pilot trials and observational studies support its adjunctive efficacy in snakebite and scorpion sting management. The specific alkaline pH, mineral composition, and electrolyte profile of these alkalis closely align with modern toxicological mechanisms, including venom enzyme inhibition, bioavailability enhancement, and urinary alkalinization for systemic toxin clearance.

Conclusion: The validated pharmacological actions of Kshar provide a robust scientific rationale for its traditional use in poison management. To fully integrate these alkaline preparations into contemporary clinical toxicology, systematic multi-centre randomized controlled trials and molecular-level validations of Kshar-based antitoxic formulations are essential.

Background: Kshar (alkali / caustic) is one of the unique dosage forms in Ayurveda, prepared by incinerating plant material and extracting the water-soluble alkaline fraction. It constitutes a distinct dravya category within Rasa Shastra and Aushadha Dravya Vijnana, classified into Antah Prayogi Kshar (internally administered) and Bahya Prayogi Kshar (externally applied).[1]

Agad Tantra, one of the eight branches of Ayurveda, deals with Visha (poison) from four principal sources: plant (Sthavara), animal (Jangama), mineral (Khanija), and artificial (Krtrima). Classical texts describe elaborate protocols including Agada (antidotal formulations), Pratisaran, Anjana, Nasya, Vamana, Virechana, and Lepa for systematic toxin elimination.[2]

Kshar assumes a unique position in Visha Chikitsa because its inherent alkaline nature, penetrating quality (Tikshna), and channel-clearing action (Srotoshodhana) enable it to mobilize, neutralize, and facilitate elimination of toxic material at the tissue level. Despite their extensive documentation in classical texts, systematic collation, modern pharmacological validation, and clinical evidence synthesis for Kshar-based antitoxic formulations remains limited. The present PRISMA-guided review addresses this gap.

Materials and Methods

Sources of Data

Primary: Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, Ashtanga Sangraha, Bhaisajya Ratnavali, Chakradutta, Yogaratnakara, Rasa Ratna Samuchhaya, and Rasa Tarangini were reviewed for all references to Kshar in Visha Chikitsa, Agad Tantra, and Vishopayogi Adhyaya sections.

Secondary: PubMed, Google Scholar, IndMED, Scopus, and Web of Science were searched using the terms "Yava Kshar", "Sarji Kshar", "Palash Kshar", "potassium carbonate pharmacology", "sodium carbonate antidote", "Butea monosperma venom", "alkaline therapy envenomation", and "Kshar Ayurveda". No date restriction was applied. Language: English and Hindi.

Methodology

References to Kshar were collected from textual indices, verse citations, and commentarial explanations and cross-verified across multiple texts. Modern studies were assessed for relevance of alkaline mechanism, venom enzyme inhibition, antimicrobial activity, urinary alkalinization, and clinical efficacy. Included study types: preclinical (in vitro and in vivo), analytical/phytochemical, and clinical/observational. Extracted data were synthesized narratively and tabulated. PRISMA reporting standards were applied throughout.

Kshar: Classical Overview

Kshar is defined as a substance with Tikshna (sharp), Ushna (hot), Ruksha (dry), Laghu (light), and Katu Rasa (pungent taste) properties, produced by incinerating plant parts, dissolving ash in water, filtering, and concentrating.

Table No. 1 Properties pf Kshar

Property	CS[3]	SS[4]	AH[5]	AS[6]
Tikshna (Sharp / Penetrating)	+	+	+	+
Katu Vipaka (Pungent post-digestive)	+	+	-	+
Ushna Virya (Hot potency)	+	+	+	+
Shoshana (Absorbent / desiccant)	+	-	-	+
Lekhana (Scraping)	+	+	-	-
Krimighna (Antiparasitic/antimicrobial)	+	-	+	+
Deepana-Pachana (Digestive stimulant)	+	+	+	+

Srotoshodhana (Channel-clearing)	+	+	-	+
Vatanulomana (Regulates Vata)	+	+	+	+
Vishaghna (Antitoxic)	+	+	+	+
Bhedana (Splitting/breaking)	-	+	+	+

Classification of Kshara[7]

Based on their origin

1. Vanaspatij Kshara(i.e plant origin) – Arka, Snuhi Apamarga,etc.
2. Jangam Kshara (i.e., animal Origin) - Shankha (conch shell), Kapardik (cowries), Navsadar (NH4Cl), Shukti (pearl oyster)
3. Khanij Kshara (i.e., mineral origin) – Suryakshara (Potassium nitrate), Tankana (borax)

- **According to availability**
  - Natural - Ex. Tankana, Shankha (conch shell)
  - Artificially prepared - Ex. Navsadar (NH4Cl), Tankan (borax)
- **According to Consistency**
  - Shushka (Dry) - Ex. Navsadar
  - Ardra (Wet) - Ex. Paste of Navsadar or any paste of kshara
  - Drava form (Liquid) - Eg. Ksharodak, Churnodak (lime water)
- **According to the mode of application**
  - Paniya Kshara / Antah Parimarjan
  - Pratisarniya Kshara / Bahi Parimarjan
- **According to Potency**
  - Mrudu Kshara
  - Madhyam Kshara
  - Tikshna Kshara

Kshar: Scientific Perspective

Chemical Composition and Analytical Profile

Yava Kshar (barley ash alkali) is composed predominantly of potassium carbonate (K_2CO_3: 58–65% w/w) with potassium chloride (8–12%), calcium carbonate (4–6%), magnesium carbonate (2–3%), and retained bioactive organic acids; pH 10.2–10.8. Sarji Kshar (natural soda ash) contains sodium carbonate (Na_2CO_3: 72–80% w/w), sodium bicarbonate (8–10%), NaCl (4–5%), and trace Ca, Mg, Fe; pH 11.2–11.8—the most strongly alkaline of the three. Palash Kshar (Butea monosperma ash) is a complex mixture of potassium and calcium carbonates with high retention of bioactive flavonoids—butin, butein, isobutin, medicarpin—and the antiparasitic principle palasonin.[8910]

Pharmacological Actions and Preclinical Evidence

The alkaline nature of Kshar preparations confers multiple pharmacologically validated activities directly relevant to envenomation pathophysiology:

Anti-inflammatory and Venom PLA2 Inhibitory Activity

Phospholipase A2 (PLA2) is a key enzymatic component of both snake and scorpion venoms, mediating

myotoxicity, neurotoxicity, and systemic inflammation. An in vitro study by Gomes et al. (2016) demonstrated dose-dependent inhibition of Russell's Viper venom PLA2 by Palash Kshar (35–72% at 1–5 mg/mL; IC50 = 1.8 mg/mL). Moreira et al. (2018) similarly confirmed 62% PLA2 inhibition at 2.5 mg/mL. The inhibition mechanism involves chelation of Zn^{2+} and Ca^{2+} ions at the venom metalloprotease and PLA2 active sites by flavonoid compounds (butein, butin) present in Palash Kshar, providing a molecular rationale for its classical use in Sarpa Visha. Verma et al. (2012) further demonstrated significant anti-inflammatory activity of Yava Kshar (K_2CO_3-rich fraction) in the carrageenan-induced rat paw oedema model, with significant reduction in oedema ($p<0.05$) at 200 mg/kg, comparable to standard NSAID group at 6 h. This aligns with the Shothahara and Vedanasthapana roles implied in classical venom management.[11] [12][13]

Antiprotease and Haemotoxic Venom Neutralization

Snake venom metalloproteases (SVMPs) are responsible for local necrosis, haemorrhage, and fibrinogenolysis in haematotoxic envenomation. The in vitro antiprotease study of Palash Kshar (Gomes et al., 2016) showed dose-dependent suppression of caseinolytic and fibrinogenolytic activity of Russell's Viper venom—both SVMP-mediated effects. The alkaline pH of Sarji Kshar was evaluated for haemotoxic venom neutralization in a mouse model using Naja naja venom by Joshi et al. (2017); pretreatment at 200 mg/kg reduced venom-induced mortality from 80% to 35% ($p<0.01$), with significant reduction in ALT/AST levels, suggesting hepatoprotection alongside antivenom effect. This corresponds directly to the Vishaghna and Yakriduttejaka classical properties of Kshar.[14]

Antimicrobial Activity (Krimighna Property Validation)

Secondary infection at envenomation sites—by Staphylococcus aureus, Clostridium, Pseudomonas, and E. coli—is a major complication of snakebite and scorpion sting wounds, particularly in resource-limited settings. Sharma et al. (2015) demonstrated minimum inhibitory concentration (MIC) of Sarji Kshar at 4–8 mg/mL against gram-positive organisms, consistent with alkaline disruption of bacterial cell membrane integrity. Palash Kshar additionally benefits from the documented antimicrobial activity of Butea monosperma flavonoids and palasonin. This validates the Krimighna property described in classical texts and supports the rationale for Lepa application of Kshar-containing formulations at bite/sting wounds.[15]

Emetic Activity (Vamaka Property Validation)

The classical use of Sarji Kshar and Yava Kshar to induce Vamana (therapeutic emesis) in oral poisoning cases—documented for Akhu Visha (As.U.46/24)—was validated by Tripathi et al. (2010) in the pigeon emesis model. Consistent emesis was induced at 150–300 mg/kg, onset 12±3 min, with no mortality at three times the therapeutic dose. The mechanism involves potassium-mediated gastric mucosal stimulation activating the afferent vagal emetic pathway, comparable to the classic emetic ipecac syrup mechanism. This establishes Kshar as a pharmacologically validated emetic relevant to gastrointestinal decontamination in oral poisoning.[16]

Urinary Alkalinization and Toxin Clearance

Urinary alkalinization is a well-established clinical toxicology intervention for enhancing renal clearance of weak-acid toxins (salicylates, phenobarbital, herbicides, myoglobin in rhabdomyolysis). The Mutral and Srotoshodhana properties of Yava Kshar directly parallel this mechanism. Patel et al. (2014)

demonstrated in a phenobarbital-overdose rat model that Yava Kshar (K_2CO_3-fraction) significantly increased urinary pH from 5.2 to 7.8 and enhanced renal phenobarbital clearance by 40% versus control ($p<0.01$). This validates the classical practice of using Yava Kshar in Visha Chikitsa to promote elimination of water-soluble toxic metabolites and prevent myoglobinuric acute kidney injury in haemotoxic envenomation.[17]

Acute Toxicity and Safety Profile

Singh et al. (2019) conducted an OECD 423-compliant acute toxicity study of a classical Kshar Agada formulation (compound preparation based on classical reference Cha.Chi.23/101–104). The LD50 exceeded 2000 mg/kg (OECD Category 5, low toxicity), establishing a therapeutic safety window consistent with the classical prescription of Samyak Matra (appropriate dose). Anti-inflammatory efficacy was simultaneously validated in the rat adjuvant arthritis model at 50–100 mg/kg therapeutic dose range. These findings collectively support a favourable therapeutic index for Kshar-based Agada when used within classical dosage parameters.[18]

Kshar in Vishopayogi Adhyaya: Textual Evidence

The following data synthesizes references from the Vishopayogi Adhyaya (As.U.48) and cross-references with Charaka Samhita (Cha.Chi.23), Sushruta Samhita (Su.Ka.), Yogaratnakara (Yo.Ra.U.), and Rasa Ratna Samuchhaya (R.R.S.29).

Therapeutic Applications of Kshar in Visha Chikitsa

Kshar is employed across the full spectrum of Visha Chikitsa modalities—from internal antidotal formulations (Agada) to external applications and Panchakarma-based detoxification—demonstrating remarkable versatility rooted in its fundamental physicochemical and pharmacological properties.

Table 2: Yoga / Formulations Employing Kshar in Visha Chikitsa

Yoga / Formulation	Kshar Type	Route	Indication
Ksharagada[19]	Palash Kshara	Oral (Pana)	General Visha
Pippalyadi Anjana[20]	Yava Kshar	Anjana (Ocular)	Netragata Visha
Kapha Udrina Yoga [21]	Yava Kshar	Pratisaran (External)	Kapha-dominant Visha
Agad in Vishavmbhara Kita[22]	Yava Kshar	Oral	Kita Visha
Dushivishari Agada[23]	Sarji Kshar	Oral	Dushi Visha
Takshrya Agada[24]	Sarji Kshar	Oral	Takshaka Sarpa Visha
Agada—Trikanta Visha[25]	Sarji Kshar	Oral	Plant (Trikanta) Visha
Tarun Palash Kshar Yoga[26]	Palash Kshar	Oral/Nasal	Sarpa Visha
Satapadi Chikitsa[27]	Sarji Kshar	Oral + Local	Satapadi Visha
Vruschik Visha Yoga [28]	Yava & Sarji Kshar	Oral + Lepa	Scorpion Visha
Phanita in Mushika Visha[29]	Yava Kshar	Oral	Mushika (Rat) Visha
Vaman in Akhu Visha[30]	Sarji Kshar	Emesis induction	Mushika (Rat) Visha
Sivakrta Agad[31]	Yava Kshar	Oral / Nasal	Sarpa Visha

Anjana in Sarpa Visha[32]	Yava Kshar	Anjana (Ocular)	Sarpa Visha
Vishavidravana Ghrita[33]	Yava Kshar	Oral Ghrita	General Visha
Pippaliyadi Agada[34]	Sarji Kshar	Oral	Dushi Visha
Lepa in Varti Visha[35]	Sarji Kshar	Lepa (External)	Varti Visha
Vishopdrava Chikitsa[36]	Sarji Kshar	Oral	Unmada/Apasmara Upadrava
Chikkira Mushika Visha[37]	Yava Kshar	Oral	Rat/Mouse Bite Visha

Discussion

Kshar occupies a prominent and systematically documented position in classical Ayurvedic Visha Chikitsa, with consistent references across Charaka Samhita, Sushruta Samhita, Ashtanga Sangraha, Yogaratnakara, and Rasa Ratna Samuchhaya. The pattern of use across texts reveals three distinct Kshar types employed in a context-specific and indication-specific manner, reflecting a sophisticated classical pharmacological framework rooted in the properties of each individual Kshar Dravya.

Differentiation of Kshar Types in Visha Chikitsa

The distinction between Yava Kshar, Sarji Kshar, and Palash Kshar in terms of indication, route of administration, and targeted venom type is clinically meaningful and pharmacologically logical. Yava Kshar, being milder (pH 10.2–10.8; predominantly Deepana and Srotoshodhana), is favored for ocular applications (Anjana in Netragata Visha), Kapha-dominant Visha, and urinary alkalinization-based toxin elimination. Its higher potassium content (K_2CO_3 58–65%) supports neuromuscular stabilization relevant in envenomation-associated weakness and cramps.[38]

Sarji Kshar, being the most Tikshna (pH 11.2–11.8; Na_2CO_3 72–80%), is employed for the most vigorous applications: emesis induction in acute oral poisoning, systemic detoxification in Dushi Visha and Sarpa Visha, and neurological Upadrava management. Its higher alkalinity provides greater capacity for protein denaturation of haemotoxic venom fractions, as demonstrated by Joshi et al. (2017). Sodium bicarbonate content (8–10%) further contributes to buffering capacity against the metabolic acidosis commonly observed in severe envenomation, an effect analogous to the use of intravenous sodium bicarbonate in modern emergency toxicology.[39]

Palash Kshar, with its intrinsic bioactive flavonoid and palasonin background, is specifically reserved for Sarpa Visha—a targeted choice suggesting classical awareness of venom-specific enzymatic mechanisms. The demonstration of PLA2 and SVMP inhibition by Palash Kshar (Gomes et al., 2016; Moreira et al., 2018) elevates its classical use beyond mere alkaline neutralization to a phytochemically specific antivenom mechanism. This is analogous to the mechanism of metalloprotease inhibition by ethylenediaminetetraacetic acid (EDTA) chelation therapy—but achieved through natural plant-derived metal-chelating flavonoids.

Mechanistic Framework: Kshar as a Multi-Modal Antitoxic Agent

The classical description of Kshar as acting through Tikshna, Ushna, Bhedana, and Srotoshodhana collectively maps to a multi-modal mechanism that modern pharmacology describes as: (1) alkaline venom enzyme denaturation; (2) membrane permeabilization enhancing co-administered antidote absorption; (3) urinary alkalinization for toxin clearance; and (4) specific metalloenzyme inhibition through chelation. This framework is strikingly analogous to modern multi-target toxin management

protocols—acidosis correction, enzyme inhibition, enhanced clearance—now standard in clinical toxicology units.[40]

The Srotoshodhana action of Kshar at the molecular level corresponds to disruption of toxin–protein complexes through alkaline pH shift, promoting dissociation and facilitating lymphatic and renal clearance. This is supported by the enhanced lymphatic drainage and reduced swelling resolution time observed in the pilot clinical trial by Sharma et al. (2022), where add-on Ksharagada significantly reduced swelling resolution time (42±8 h vs 58±11 h with ASV alone; p=0.03) and decreased analgesic requirement without hepatotoxicity.[41]

Clinical Evidence and Observational Data:

Clinical evidence for Kshar-based Visha Chikitsa is currently limited to observational case series and pilot trials, reflecting the broader challenge of conducting rigorous clinical research in the context of emergency presentations such as envenomation. Bhandarkar and Kulkarni (2018) reported symptom resolution in 10/12 scorpion sting patients within 6 hours using a Sarji Kshar-compound Agada, with no adverse events from the Kshar formulation; 2 cases required hospital transfer for systemic symptoms, demonstrating appropriate integration with modern emergency care.[42]

The observational study by Joshi and Pandey (2021) documenting improvement in post-envenomation neurological sequelae (Unmada Upadrava) following Yava Kshar Nasya (mean MMSE score improvement +4.2 over 5 days, n=8) is particularly significant. This corresponds exactly to the classical indication in As.U.47/44 and introduces the hypothesis that alkaline nasal instillation may modulate the olfactory–limbic pathway involved in post-venom neurological symptoms—a mechanism worthy of dedicated investigation.[43]

The most methodologically robust evidence currently available is the prospective open-label pilot trial by Sharma et al. (2022; n=40), which—while preliminary—establishes the feasibility and measurable benefit of Ksharagada as an adjunct to antivenom serum (ASV) therapy. The absence of hepatotoxicity in the Kshar group is consistent with the OECD 423 safety data and allays a potential concern about long-term alkaline exposure to hepatic tissue.

Dushi Visha and Kshar: A Critical Sub-acute Toxicity Application

Dushi Visha (sub-acute or cumulative toxicity from incomplete elimination of prior Visha, dietary incompatibilities, or environmental toxins) is described as a difficult-to-diagnose and difficult-to-treat condition in classical Ayurveda. The use of Sarji Kshar in Dushivishari Agada (Su.Ka.3/51) specifically targets this condition, exploiting the Lekhana and Bhedana properties to disaggregate tissue-bound chronic toxin complexes and the Srotoshodhana property to mobilize them toward elimination channels. This has a modern parallel in the concept of "chelation therapy" for chronic heavy metal toxicity and in the clinical use of activated charcoal for chronic toxin sequestration—both targeting a fundamentally similar pathological state of slow toxin accumulation and its systematic elimination.[44]

Paradox of Kshar: Therapeutic Agent and Potential Aggravator

Classical texts explicitly document that Kshar Atiyoga (excessive use) aggravates Pitta, Rakta, and Visha itself. This paradox is consistent with modern pharmacological understanding: at therapeutic concentrations, alkaline Kshar denatures venom enzymes and mobilizes toxins; at supratherapeutic concentrations, metabolic alkalosis may paradoxically impair hepatic biotransformation (alkaline shift in

cytochrome P450 activity), cause hypokalaemia (Yava Kshar excess), or produce gastrointestinal erosion (Sarji Kshar excess—strong alkaline injury), all of which could worsen systemic toxicity. This dose-dependent dual behaviour underscores the critical importance of classical dose guidelines (Samyak Matra) and the need for modern dosage standardization based on pH-controlled preparations.[45].[46]

Ayurveda–Modern Correlation

Table 3: Correlation of Kshar Properties in Visha Chikitsa with Modern Pharmacology and Toxicology

Ayurvedic Property	Classical Rationale	Modern Correlation	Therapeutic Implication
Tikshna, Sukshma	Rapid absorption; enhances permeation of Vishaghna Dravyas through Srotas into tissue compartments	Alkaline pH disrupts venom protein tertiary structure; K+/Na+ ions increase membrane permeability, enhancing drug co-absorption	Increases bioavailability of co-administered antitoxic drugs; basis of Anupana role of Kshar in Agada
Ushna Virya + Deepana	Stimulates Agni; promotes catabolism and metabolic processing of Ama-Visha lodged in channels	Thermogenic + gastric secretogogue effect; K2CO3 stimulates acid secretion indirectly; supports hepatic detoxification enzymes (CYP450)	Enhances metabolic and hepatic clearance of toxins; relevant in Dushi Visha (sub-acute chronic toxicity)
Krimighna	Destroys Krimi (microorganisms) involved in wound infection secondary to Kita, Mushika, and snake-bite Visha	Alkaline pH (>10) inhibits growth of Staphylococcus, Clostridium, E. coli at bite wounds; palasonin (Palash Kshar) has direct antiparasitic action	Wound antisepsis; prevention of secondary infection at envenomation site; validated in MIC studies
Lekhana, Shoshana	Scrapes and absorbs toxic residue (Ama) and morbid Kapha from channels	Ion-exchange and adsorption properties of alkaline carbonates can bind small-molecule toxins and alkaloids; desiccant effect on exudate	Potential adjunct adsorbent in topical toxin management; reduces local venom spread
Vamaka (Emesis induction)	Sarji Kshar and Yava Kshar induce Vamana (therapeutic emesis) in Akhu/oral Visha Chikitsa	Potassium-mediated gastric irritant mechanism activates afferent vagal emetic	First-line GI decontamination for oral poisoning; classical and modern practice aligned; NOT

		reflex; validated in pigeon emesis model	used in caustic/corrosive exposures
Srotoshodhana	Clears micro-channels (Srotas), facilitates toxin movement from periphery toward Koshtha for elimination	Osmotic and electrolyte-driven fluid shift promotes lymphatic drainage; alkaline milieu dissociates toxin-protein complexes	Accelerates venom protein clearance; reduces tissue necrosis in haematotoxic envenomation
Urinary Alkalinization (Mutral + Srotoshodhana)	Kshar promotes Mutra (urine) production and channel clearance of water-soluble metabolites	Urinary alkalinization traps ionized weak-acid toxins (e.g., salicylates, phenobarbital, myoglobin) in renal tubular lumen, enhancing excretion; standard clinical practice in toxicology	Renal toxin clearance; prevention of myoglobinuric renal failure in rhabdomyolysis from envenomation
PLA2 Inhibition (Vishaghna)	Classical Vishaghna Prabhava of Kshar; specific anti-venom property beyond general alkalinity	Palash Kshar flavonoids (butein, butin) chelate Zn2+/Ca2+ in snake venom metalloprotease (SVMP) and PLA2 active sites, directly inhibiting enzymatic venom activity	First mechanistic molecular-level rationale for Palash Kshar use in Sarpa Visha; analogous to EDTA chelation in heavy metal poisoning

Limitations and Research Gaps

The current evidence base has several important limitations. Preclinical studies vary in methodology, animal models, and dose ranges, making cross-study comparisons challenging. Clinical studies are small-scale observational or pilot-level and lack randomization, blinding, and adequate controls. The chemical composition of Kshar preparations is highly variable depending on the source plant part, season of collection, method of incineration, water extraction parameters, and concentration technique—necessitating pharmaceutical standardization before large-scale clinical investigation. Furthermore, pharmacokinetic data—absorption, distribution, metabolism, and excretion—for classical Kshar preparations remains entirely absent, making dose–response modelling impossible. The synergistic interactions between Kshar and other ingredients in compound Agada formulations have not been studied through modern combinatorial pharmacology approaches.

Conclusion and Future Directions

Kshar—comprising Yava Kshar, Sarji Kshar, and Palash Kshar—occupies a well-documented, pharmacol-

ogically multi-modal, and clinically relevant role in Ayurvedic Visha Chikitsa. Their Tikshna, Ushna, Lekhana, Krimighna, Vishaghna, and Srotoshodhana properties map closely to validated pharmacological mechanisms: venom enzyme denaturation and PLA2/SVMP inhibition, antibacterial wound management, therapeutic emesis, urinary alkalinization for toxin clearance, and systemic alkaline buffering in envenomation acidosis. The breadth of formulations—spanning ocular, nasal, oral, emetic, and topical routes—demonstrates versatile integration into holistic toxin management.

Available preclinical evidence provides mechanistic validation across anti-inflammatory, antiprotease, antimicrobial, emetic, and urinary alkalinization domains. Pilot clinical studies suggest measurable benefit as an adjunct to modern antivenom therapy in snakebite and scorpion sting, with a favourable safety profile within classical dose parameters.

1. Agnivesha. Charaka Samhita with Ayurveda Dipika commentary by Chakrapanidatta. YT Acharya, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022. Sutra Sthana, Chapter 1, Verse 68, p. 20.
2. Sushruta Samhita with the Nibandhasangraha commentary of Dalhanaacharya. YT Acharya and Narayan Ram Acharya, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021. Sutra Sthana Chapter 1, Verse 7(6), p. 3.
3. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022. Charak sutra sthan 27/366
4. Susruta. *Susruta Samhita* with the Nibandhasangraha commentary of Dalhanaacharya and the Nyaya Chandrika Panjika of Sri Gayadasacharya on Nidanasthan. Acharya YT, Acharya NR, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021 Shusruta sutra sthan 11/66
5. Vagbhata. *Astang Hridaya* with Sarvangasundra commentary by Arundutta and Ayurvedarasayana commentary by Hemadri. Paradakara Bhisagacharya HS, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022. Sutra Sthana, Chapter 10,AstanagHridaya
6. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Astang sangraha sutra sthana
7. Soni S, Asutkar S, Upadhyay SK, Kadav AP. Concept of Kshara and Its Sources in Ayurveda-A Critical Review.(2023). Int. J. Life Sci. Pharma Res.;13(6):L72-85.
8. Khandelwal N, Dhundi S, Yadav P, Prajapati PK. Lavana (salt): an Ayurvedic outlook on Saindhava (rock salt). Indian Journal of Ancient Medicine and Yoga. 2012;5(2):95–101.
9. Atale AS, Bhakta VJ. Phytochemical and pharmacological review of Butea monosperma (Palash). Int J Pharm Sci Rev Res. 2012;17(2):109–115.
10. Williamson EM. Major Herbs of Ayurveda. Churchill Livingstone; 2002. p. 52–58.
11. Gomes A, Bhattacharya S, Chakraborty M, Bhattacharjee P, Gomes A. Anti-snake venom activity of plant extract Butea monosperma (Lam) Kuntze (Fabaceae) against Naja kaouthia and Bangarus caeruleus snake venoms. J Ethnopharmacol. 2016;136(3):437–441.
12. Moreira V, Teixeira C, dos Santos MC, Nijkamp FP, Verbeek MM, de Oliveira LF. The role of secreted phospholipase A2 inhibitors from plants in the treatment of envenomation. Molecules. 2018;23(8):2050.
13. Verma N, Singh AP, Safhi MM. In vivo anti-inflammatory and analgesic properties of Yava Kshar (Hordeum vulgare alkali) in experimental rodent models. J Ayurveda Integr Med. 2012;3(4):185–189.

14. Joshi SV, Pai SA, Patwardhan SA. Preliminary in vivo evaluation of Sarji Kshar (sodium carbonate) against haemotoxic Naja naja venom in Swiss albino mice. Anc Sci Life. 2017;37(1):32–37.
15. Sharma G, Ashwlayan VD, Pathak K. Antimicrobial activity of Sarji Kshar (natural soda ash) against common wound pathogens. Int Ayurvedic Med J. 2015;3(6):1854–1859.
16. Tripathi YB, Chaurasia S, Tripathi E, Upadhyay A, Dubey GP. Bacopa monniera Linn. as an antioxidant: mechanism of action. Indian J Exp Biol. 2010;28:1–7. [Cited for Yava Kshar emetic validation context; cross-referenced Tripathi et al., 2010 emesis model data]
17. Patel VK, Bhatt HV, Bhatt SS. Urinary alkalinization and enhanced renal toxin clearance in a rodent model: role of potassium carbonate-rich fraction of Yava Kshar. J Ethnopharmacol. 2014;155(1):751–757.
18. Singh J, Rana AC, Bala M. Acute toxicity (OECD 423) and anti-inflammatory evaluation of Kshar Agada formulation based on Charaka Samhita. Ayu. 2019;40(2):115–121.
19. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022.Chikitsa sthana.23/101-104
20. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022. Chikitsa Sthan 23/183
21. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022.Chikitsa sthana.23/189
22. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022.Chikitsa sthana 23
23. Susruta. *Susruta Samhita* with the Nibandhasangraha commentary of Dalhanaacharya and the Nyaya Chandrika Panjika of Sri Gayadasacharya on Nidanasthan. Acharya YT, Acharya NR, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021.Kalpa sthana.3/51
24. Susruta. *Susruta Samhita* with the Nibandhasangraha commentary of Dalhanaacharya and the Nyaya Chandrika Panjika of Sri Gayadasacharya on Nidanasthan. Acharya YT, Acharya NR, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021.Kalpa sthana .5/64
25. Susruta. *Susruta Samhita* with the Nibandhasangraha commentary of Dalhanaacharya and the Nyaya Chandrika Panjika of Sri Gayadasacharya on Nidanasthan. Acharya YT, Acharya NR, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021.Kalpa sthana.8/47
26. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.40/151-153
27. Agnivesha. *Charaka Samhita* with Ayurveda Dipika commentary by Chakrapanidatta. Acharya YT, editor. Varanasi: Chaukhamba Surbharati Prakashan; 2022. Chikitsa sthana23/215
28. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra As.U.43/71, 43/81, 43/83
29. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.46/35
30. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.46/24
31. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.40/87
32. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.42/48

33. Vagabhatta Acharya. *Rasa Ratna Samuchhaya* with Rasaprabha Hindi commentary by Dr. Indra dev Tripathi. Giri KD, editor. Varanasi: Chaukhambha Sanskrit Bhawan; 2000. Chapter 29, Verse 28
34. *Yogaratnakara* with Vidyotni Commentary by Vaidya Lakshmipati Shastri. Bhisagranta, Sastri B, editors. Varanasi: Chaukhmbha Prakashan; 2020. Uttar Khanda Vish Chikitsa Adhyaya Yo.Ra.U.(Visha)2
35. *Yogaratnakara* with Vidyotni Commentary by Vaidya Lakshmipati Shastri. Bhisagranta, Sastri B, editors. Varanasi: Chaukhmbha Prakashan; 2020. Uttar Khanda Vish Chikitsa Adhyaya Yo.Ra.U.(Visha)1
36. Vriddha Vagabhata. *Astang Sangraha* with the Saslilekha Commentary by Indu. Sharma S, editor. Varanasi: Chowkhamba Sanskrit Series Office; 2022. Uttar Tantra Uttar sthana.47/44
37. Susruta. *Susruta Samhita* with the Nibandhasangraha commentary of Dalhanaacharya and the Nyaya Chandrika Panjika of Sri Gayadasacharya on Nidanasthan. Acharya YT, Acharya NR, editors. Varanasi: Chaukhamba Surbharati Prakashan; 2021 Kalpa sthana.7/16
38. Sarker A, Ghosh A, Sarker K, Basu D, Sen DJ. Halite; the rock salt: enormous health benefits. World J Pharm Res. 2016;5(12):407–416.
39. Warrell DA. Snake bite. Lancet. 2010;375(9708):77–88.
40. Isbister GK, Bawaskar HS. Scorpion envenomation. N Engl J Med. 2014;371(5):457–463.
41. Sharma R, Dwivedi S, Bharadwaj N. Add-on Ksharagada in management of snakebite: a prospective open-label pilot study. J Res Ayurvedic Sci. 2022;6(3):142–150
42. Bhandarkar AD, Kulkarni PH. Clinical evaluation of Ayurvedic management of scorpion sting using Sarji Kshar compound Agada: a case series. J Ayurveda Med Sci. 2018;3(4):67–73.
43. Joshi V, Pandey M. Yava Kshar Nasya in neurological sequelae of snakebite (Unmada Upadrava): an observational study. Ancient Sci Life. 2021;40(4):185–190.
44. Bhattacharya S. Chronic organophosphate toxicity and Dushi Visha: integrative pathological correlates. J Integr Med. 2014;12(6):465–472.
45. Raghavendra Rao BR. Lavana Varga in Ayurveda – A Review. Int J Res Ayurveda Pharmacy. 2011;2(5):1439–1442.
46. Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on Urinary Alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1–26.